Pages that link to "Q77348864"

The following pages link to Rebamipide protects against indomethacin-induced gastric mucosal injury in healthy volunteers in a double-blind, placebo-controlled study (Q77348864):

Displaying 29 items.

• Up-to-date information on gastric mucosal lesions from long-term NSAID therapy in orthopedic outpatients: a study using logistic regression analysis (Q28218938) (← links)
• Transcriptome Analysis for Cytoprotective Actions of Rebamipide against Indomethacin-Induced Gastric Mucosal Injury in Rats. (Q30841417) (← links)
• Rebamipide significantly inhibits indomethacin-induced mitochondrial damage, lipid peroxidation, and apoptosis in gastric epithelial RGM-1 cells (Q33223955) (← links)
• Efficacy of Albis for the Prevention of Gastric Mucosal Injury Concomitant with the Use of Low-Dose Aspirin: A Prospective, Randomized, Placebo-Controlled Study (Q33583991) (← links)
• Effect of aspirin cessation before endoscopy in Japanese patients with low-dose-aspirin-associated gastroduodenal mucosal injury (Q33695564) (← links)
• Rebamipide ophthalmic suspension for the treatment of dry eye syndrome: a critical appraisal (Q33734688) (← links)
• Preventive efficacy and safety of rebamipide in nonsteroidal anti-inflammatory drug-induced mucosal toxicity (Q33959603) (← links)
• Evaluation of dacryocystorhinostomy using optical coherence tomography and rebamipide ophthalmic suspension (Q34028368) (← links)
• Rebamipide helps defend against nonsteroidal anti-inflammatory drugs induced gastroenteropathy: a systematic review and meta-analysis (Q34606022) (← links)
• Rebamipide does not protect against naproxen-induced gastric damage: a randomized double-blind controlled trial (Q36040552) (← links)
• 15th anniversary of rebamipide: looking ahead to the new mechanisms and new applications (Q36268036) (← links)
• Global analysis of gene expression in gastric ischemia-reperfusion: a future therapeutic direction for mucosal protective drugs (Q36268048) (← links)
• Preliminary trial of rebamipide for prevention of low-dose aspirin-induced gastric injury in healthy subjects: a randomized, double-blind, placebo-controlled, cross-over study (Q37327687) (← links)
• Cellular membrane fluidity measurement by fluorescence polarization in indomethacin-induced gastric cellular injury in vitro (Q40034665) (← links)
• Prevention of Indomethacin-Induced Gastric Mucosal Injury in Helicobacter pylori-Negative Healthy Volunteers: A Comparison Study Rebamipide vs Famotidine (Q40087299) (← links)
• Effect of Rebamipide on the Premalignant Progression of Chronic Gastritis: A Randomized Controlled Study (Q41000823) (← links)
• Comparison of Prevention of NSAID-Induced Gastrointestinal Complications by Rebamipide and Misoprostol: A Randomized, Multicenter, Controlled Trial-STORM STUDY. (Q41979931) (← links)
• Alterations of epithelial permeability by Helicobacter and IL-1beta in vitro: protective effect of rebamipide (Q42507928) (← links)
• Relationship between low-dose aspirin-induced gastric mucosal injury and intragastric pH in healthy volunteers (Q43293550) (← links)
• Efficacy of rebamipide for diclofenac-induced small-intestinal mucosal injuries in healthy subjects: a prospective, randomized, double-blinded, placebo-controlled, cross-over study (Q43871043) (← links)
• Long-term rebamipide therapy improves Helicobacter pylori-associated chronic gastritis (Q43980787) (← links)
• An open-labeled study of rebamipide treatment in chronic gastritis patients with dyspeptic symptoms refractory to proton pump inhibitors (Q46615410) (← links)
• Rebamipide, a gastro-protective drug, inhibits indomethacin-induced apoptosis in cultured rat gastric mucosal cells: association with the inhibition of growth arrest and DNA damage-induced 45 alpha expression (Q46720913) (← links)
• Using human iPS cell-derived enterocytes as novel in vitro model for the evaluation of human intestinal mucosal damage (Q57468646) (← links)
• Assessing the efficacy of famotidine and rebamipide in the treatment of gastric mucosal lesions in patients receiving long-term NSAID therapy (FORCE--famotidine or rebamipide in comparison by endoscopy) (Q79745265) (← links)
• Preventive effects of rebamipide on NSAID-induced gastric mucosal injury and reduction of gastric mucosal blood flow in healthy volunteers (Q80102019) (← links)
• Gastric injury caused by low-dose aspirin therapy in consecutive Japanese patients: a prospective study (Q83754936) (← links)
• Association between adherence to evidence-based guidelines for the prescription of non-steroidal anti-inflammatory drugs and the incidence of gastric mucosal lesions in Japanese patients (Q84293313) (← links)
• A randomized, double-blind, placebo-controlled study of rebamipide for gastric mucosal injury taking aspirin with or without clopidogrel (Q87498644) (← links)